For example, the strong effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs; i.e., gefitinib and erlotinib) on non-small-cell lung cancer (NSCLC) are correlated with activating somatic mutations in EGFR [1,2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.